Literature DB >> 12827038

Effects of arginine vasopressin on growth of rat cardiac fibroblasts: role of V1 receptor.

Xue-Dong Yang1, Lian-You Zhao, Qiang-Sun Zheng, Xue Li.   

Abstract

The abnormal proliferation of cardiac fibroblasts is involved in the pathophysiologic process of left ventricular hypertrophy (LHV) associated with essential hypertension. Arginine vasopressin (AVP) has been reported to contribute significantly to the pathogenesis of hypertension. In this study, the authors investigated the effects of AVP and its V1 receptor antagonist [d(CH2)5Tyr2(Me)]AVP on the growth of rat cardiac fibroblasts. Cardiac fibroblasts of neonatal Sprague-Dawley rats were isolated, and growth-arrested cardiac fibroblasts were stimulated with 2.5% fetal calf serum in the presence and absence of AVP (0.001, 0.01, 0.1, and 1 microM) and [d(CH2)5Tyr2(Me)]AVP (0.1 microM). DNA synthesis was measured by [3H]thymidine incorporation. Thiazolyl blue assay and flow cytometry techniques were adopted to measure cell numbers and analyze cell cycle, respectively. Arginine vasopressin (0.1 and 1 microM) significantly increased DNA synthesis in cardiac fibroblasts. Moreover, AVP (0.1 and 1 microM) significantly increased the number of cardiac fibroblasts. Analysis of cell cycle showed that AVP (0.1 microM) increased S-stage percentage and proliferation index (PI). The V1 receptor antagonist [d(CH2)5Tyr2(Me)]AVP (0.1 microM) significantly inhibited DNA synthesis in cardiac fibroblasts. The cell number, S-stage percentage, and PI induced by AVP (0.1 microM) were significantly decreased by [d(CH2)5Tyr2(Me)]AVP (0.1 microM). These findings suggest that AVP might promote the proliferation of rat cardiac fibroblasts, which seems to be mediated via the V1 receptor. Arginine vasopressin may be involved in the pathophysiologic process of LVH by promoting cardiac fibroblast proliferation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12827038     DOI: 10.1097/00005344-200307000-00020

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  10 in total

1.  Outcomes of correcting hyponatremia in patients with myocardial infarction.

Authors:  Waqas Qureshi; Syed Hassan; Fatima Khalid; Mohamed Faher Almahmoud; Bhavik Shah; Ra'ad Tashman; Nikhil Ambulgekar; Mostafa El-Refai; Chetan Mittal; Zaid Alirhayim
Journal:  Clin Res Cardiol       Date:  2013-05-08       Impact factor: 5.460

Review 2.  Arginine vasopressin as a target in the treatment of acute heart failure.

Authors:  Nisha A Gilotra; Stuart D Russell
Journal:  World J Cardiol       Date:  2014-12-26

3.  Caveolin-1 restoration by cholesterol enhances the inhibitory effect of simvastatin on arginine vasopressin-induced cardiac fibroblasts proliferation.

Authors:  Shaowei Liu; Yanping He; Yufeng Dou; Haichang Wang; Ling Tao; Lianyou Zhao; Fujun Shang; Hui Liu
Journal:  Mol Cell Biochem       Date:  2009-05-18       Impact factor: 3.396

4.  Involvement of ERK and AKT signaling in the growth effect of arginine vasopressin on adult rat cardiac fibroblast and the modulation by simvastatin.

Authors:  Yan-Ping He; Lian-You Zhao; Qiang-Sun Zheng; Shao-Wei Liu; Xiao-Yan Zhao; Xiao-Long Lu; Xiao-Lin Niu; Xia Li
Journal:  Mol Cell Biochem       Date:  2008-06-26       Impact factor: 3.396

5.  Sodium levels during hospitalization with acute myocardial infarction are markers of in-hospital mortality: Soroka acute myocardial infarction II (SAMI-II) project.

Authors:  Ygal Plakht; Harel Gilutz; Arthur Shiyovich
Journal:  Clin Res Cardiol       Date:  2018-05-15       Impact factor: 5.460

Review 6.  Arginine vasopressin receptor signaling and functional outcomes in heart failure.

Authors:  Melissa A Wasilewski; Valerie D Myers; Fabio A Recchia; Arthur M Feldman; Douglas G Tilley
Journal:  Cell Signal       Date:  2015-07-30       Impact factor: 4.315

Review 7.  Short- and long-term prognostic value of hyponatremia in patients with acute coronary syndrome: A systematic review and meta-analysis.

Authors:  Qiang-Qiang Ma; Xiu-De Fan; Tao Li; Yuan-Yuan Hao; Feng Ma
Journal:  PLoS One       Date:  2018-03-02       Impact factor: 3.240

8.  β-Arrestin 2 mediates arginine vasopressin-induced IL-6 induction via the ERK1/2-NF-κB signal pathway in murine hearts.

Authors:  Shu-Zhen Sun; Hong Cao; Na Yao; Ling-Ling Zhao; Xiao-Fang Zhu; Er-An Ni; Qi Zhu; Wei-Zhong Zhu
Journal:  Acta Pharmacol Sin       Date:  2019-09-12       Impact factor: 6.150

Review 9.  The Biology of Vasopressin.

Authors:  Samantha Sparapani; Cassandra Millet-Boureima; Joshua Oliver; Kathy Mu; Pegah Hadavi; Tamar Kalostian; Nazifa Ali; Carla Maria Avelar; Marion Bardies; Brenton Barrow; Minky Benedikt; Giuliana Biancardi; Raminder Bindra; Lisa Bui; Zakaria Chihab; Ashley Cossitt; Jeffrey Costa; Tina Daigneault; Jocelyn Dault; Isa Davidson; Jonathan Dias; Emie Dufour; Sabine El-Khoury; Nargess Farhangdoost; Anika Forget; Alexa Fox; Myriam Gebrael; Maria Concetta Gentile; Olivia Geraci; Ansley Gnanapragasam; Elias Gomah; Elie Haber; Claudia Hamel; Thivya Iyanker; Christina Kalantzis; Sara Kamali; Elsa Kassardjian; Hryssi Krissy Kontos; Thi Bich Uyen Le; Daniella LoScerbo; Yan Fang Low; Danielle Mac Rae; Flore Maurer; Sana Mazhar; Alice Nguyen; Kathy Nguyen-Duong; Chelsea Osborne-Laroche; Hwi Wun Park; Emilie Parolin; Kahlila Paul-Cole; Leah Sarah Peer; Margaux Philippon; Charles-Alexandre Plaisir; Jessica Porras Marroquin; Simran Prasad; Rewaparsad Ramsarun; Saad Razzaq; Samantha Rhainds; Damien Robin; Ryan Scartozzi; Davindra Singh; Sajad Soleimani Fard; Maxim Soroko; Nastaran Soroori Motlagh; Kiri Stern; Laila Toro; M Wyatt Toure; Stephanie Tran-Huynh; Sarah Trépanier-Chicoine; Claudia Waddingham; Aaliyah Jasmine Weekes; Allison Wisniewski; Chiara Gamberi
Journal:  Biomedicines       Date:  2021-01-18

10.  Arterial plasma vasopressin and aldosterone predict left ventricular mass in men who develop hypertension over 20 years.

Authors:  Arne H Strand; Helga Gudmundsdottir; Eigil Fossum; Ingrid Os; Reidar Bjørnerheim; Sverre E Kjeldsen
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-05       Impact factor: 3.738

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.